Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 1/20 | 0.51 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | ACHE | P22303 | 1/20 | 0.49 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | VDR | P11473 | 5/20 | 0.45 |
| ▸ | AR | P10275 | 4/20 | 0.45 |
| ▸ | ADRB2 | P07550 | 3/20 | 0.45 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22639837 | 1.00 | PKM (0.52) | PKMGLAMAPTSLC2A1L3MBTL1 | |
| SCHEMBL12215557 | 0.85 | SLC2A1 (0.57) | PKMGLAMAPTSLC2A1L3MBTL1 | |
| SCHEMBL11223419 | 0.84 | ADRB2 (0.62) | MAPTCYP2D6MEN1KMT2AADRB2 | |
| SCHEMBL11743303 | 0.82 | HTR1A (0.57) | PKMSLC2A1L3MBTL1CYP2D6MEN1 | |
| SCHEMBL22639720 | 0.81 | PKM (0.63) | PKMSLC2A1CYP2D6MEN1KMT2A | |
| SCHEMBL22639888 | 0.81 | PKM (0.63) | PKMSLC2A1CYP2D6MEN1KMT2A | |
| SCHEMBL11121575 | 0.80 | KMT2A (0.61) | MAPTMEN1KMT2AVDRAR | |
| SCHEMBL11865182 | 0.78 | L3MBTL1 (0.67) | GLAMAPTSLC2A1L3MBTL1ACHE | |
| SCHEMBL12215556 | 0.77 | ACHE (0.74) | GLAMAPTL3MBTL1ACHECYP2D6 | |
| SCHEMBL11489571 | 0.77 | CYP2D6 (0.71) | MAPTCYP2D6MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | Friedrich-Alexander-Universität Erlangen-Nürnberg (DE) | 2020-11-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10828281-B2 | Non-hydrophobic compounds for use in treating metastasis and/or cartilage defect | VIM, MATR3, TP53 | PKM 846/4885GLA 1517/4885MAPT 168/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.